Literature DB >> 10550187

Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi.

J Humphries1, C L McGuinness, A Smith, M Waltham, R Poston, K G Burnand.   

Abstract

PURPOSE: Organization, recanalization, and contraction are common to wound healing and thrombus resolution. Monocytes are essential to wound healing and are also found in venous thrombi. We measured endogenous levels of the monocyte chemotactic protein-1 (MCP-1) in naturally resolving venous thrombi and determined the effect of injecting MCP-1 into newly formed thrombus.
METHODS: Endogenous MCP-1 levels were estimated in rat blood, thrombi, and the adjacent vessel wall after thrombus formation, in cohorts of eight animals at 1, 7, and 14 days. In another group (n = 10), 1 microgram of MCP-1 was injected into newly formed thrombi. Carrier was injected into the thrombi of control animals (n = 10). Thrombi and adjacent vein walls were obtained for histology at 7 days. Thrombi were given an arbitrary organization score based on erythrocyte and extracellular matrix content, which was assessed by means of computerized and observer analysis. Specimen weight, thrombus area, and cellular and monocyte content were measured.
RESULTS: Endogenous MCP-1 increased between days 1 and 7 in the thrombus (1-day median, 1.1 ng/g wet wt; 1-day range, 0.8 to 1.4 ng/g wet wt; 7-day median, 5.4 ng/g wet wt; 7-day range, 1.5 to 7.4 ng/g wet wt; P <.0001) and vein wall (1-day median, 1.5 ng/g wet wt; 1-day range, 0.8 to 4.3 ng/g wet wt; 7-day median, 3.3 ng/g wet wt; 7-day range, 2.7 to 8.3 ng/g wet wt; P <. 05). At 14 days, thrombus was incorporated in the vein wall, and total MCP-1 levels remained high (median, 3.9 ng/g wet wt; range, 1.1 to 7.4 ng/g wet wt). Less MCP-1 was found in the thrombus than the adjacent vessel wall at day 1 (P <.05), but there was no difference at day 7. MCP-1 could not be detected in the blood. MCP-1 injection into thrombus increased the computer (P =.016) and observer (P =.004) organization scores, reduced the thrombus area (from median, 3. 4 mm(2), and range, 1.5 to 5.7 mm(2), to median, 0.2 mm(2), and range, 0.02 to 2.6 mm(2); P =.048), and increased the surrounding vessel wall monocyte content (P =.008). Specimen weights of treated animals were lower than those of control animals (P <.02).
CONCLUSION: Venous thrombus MCP-1 levels increase during natural resolution. MCP-1 treatment increased the organization and resolution of thrombi. MCP-1 may therefore be of therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550187     DOI: 10.1016/s0741-5214(99)70014-5

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  21 in total

1.  Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis.

Authors:  Gerald A Hish; Jose A Diaz; Angela E Hawley; Daniel D Myers; Patrick A Lester
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction.

Authors:  J Gabre; C Chabasse; C Cao; S Mukhopadhyay; S Siefert; Y Bi; S Netzel-Arnett; R Sarkar; L Zhang
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

3.  Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Yumi Kuninaka; Masanori Inui; Naofumi Mukaida; Toshikazu Kondo
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

4.  A biomechanical analysis of venous tissue in its normal and post-phlebitic conditions.

Authors:  Kirk C McGilvray; Rajabrata Sarkar; Khanh Nguyen; Christian M Puttlitz
Journal:  J Biomech       Date:  2010-09-22       Impact factor: 2.712

5.  Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging.

Authors:  Crystal M Ripplinger; Chase W Kessinger; Chunqiang Li; Jin Won Kim; Jason R McCarthy; Ralph Weissleder; Peter K Henke; Charles P Lin; Farouc A Jaffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-20       Impact factor: 8.311

6.  Myeloid cell tissue factor does not contribute to venous thrombogenesis in an electrolytic injury model.

Authors:  Anna L Hampton; Jose A Diaz; Angela E Hawley; Shirley K Wrobleski; Jian-Guo Wang; Rebecca D Lee; Daniel Kirchhofer; Robert E Sigler; Thomas W Wakefield; Nigel Mackman; Daniel D Myers
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

7.  Effects of stenting the parent artery on aneurysm filling and gene expression of various potential factors involved in healing of experimental aneurysms.

Authors:  T Darsaut; I Salazkin; C Ogoudikpe; G Gevry; F Bouzeghrane; J Raymond
Journal:  Interv Neuroradiol       Date:  2007-01-19       Impact factor: 1.610

8.  Endovascular Treatment with Platinum Coils. Recanalization is Associated with Early Increased von Willebrand Factor mRNA.

Authors:  J Raymond; C Ogoudikpe; A Metcalfe; I Salazkin; G Gevry; O Robledo
Journal:  Interv Neuroradiol       Date:  2006-07-31       Impact factor: 1.610

Review 9.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

10.  Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.

Authors:  Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith
Journal:  J Vasc Surg       Date:  2009-08-22       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.